Novartis still hasn’t solved its CAR-T manufacturing issues
Lingering difficulties in making all Kymriah product to FDA specifications has meant Novartis can’t always charge for the cell therapy. New data at ASH could help the pharma’s case.
Related Articles
Phase I study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult B-ALL patients
Key Points. JCAR021 led to high response rates in R/R adult B-ALL that were durable in low marrow burden patients receiving higher CAR T-cell dosesOutcomes
Fauxcoll gradient
Fauxcoll gradient, Blood, Volume 115, Issue 13, 1 April 2010, Pages 2567, https://doi.org/10.1182/blood-2010-03-272575
Development and validation of predictive models of early immune effector cell-associated hematotoxicity (eIPMs)
Key Points. Disease type, baseline cytopenia, lymphodepletion intensity, and systemic inflammation were strongly associated with severe early ICAHT.We vali
Development and validation of predictive models of early immune effector cell-associated hematotoxicity (eIPMs)
Key Points. Disease type, baseline cytopenia, lymphodepletion intensity, and systemic inflammation were strongly associated with severe early ICAHT.We vali
Development and validation of predictive models of early immune effector cell-associated hematotoxicity (eIPMs)
Key Points. Disease type, baseline cytopenia, lymphodepletion intensity, and systemic inflammation were strongly associated with severe early ICAHT.We vali
Hindsight Bias – The Decision Lab
Hindsight bias, or the knew-it-all-along, is the tendency to claim currents events were to happen even though it was completely unpredictable in the past.
CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study
This trial identifies CD22 as an immunotherapeutic target in large B-cell lymphoma and demonstrates the durable clinical activity of CAR22 in patients with disease progression…
CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study
This trial identifies CD22 as an immunotherapeutic target in large B-cell lymphoma and demonstrates the durable clinical activity of CAR22 in patients with disease progression…